Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External Validation and Recalibration of a Risk Calculator for Major Bleeding After Diagnostic Kidney Biopsy.

Kidney medicine·2026
Same author

Genetic testing in kidney transplantation and living kidney donor risk assessment.

Kidney international·2026
Same author

Correction: Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada.

Frontiers in immunology·2025
Same author

Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada.

Frontiers in immunology·2025
Same author

Blood Biomarkers to Identify Renal Angiomyolipomas in People With Tuberous Sclerosis Complex.

Neurology. Genetics·2025
Same author

Renal cell carcinoma with fibromyomatous stroma (RCC FMS) and with hemangioblastoma-like areas is part of the RCC FMS spectrum in patients with tuberous sclerosis complex.

Histopathology·2025
Same journal

Aortic Valve Replacement in Women of Reproductive Age.

Journal of the American College of Cardiology·2026
Same journal

Sudden Death in Cardio-Kidney-Metabolic Patients: Insights From FINE-HEART.

Journal of the American College of Cardiology·2026
Same journal

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.

Journal of the American College of Cardiology·2026
Same journal

Reframing Cardiometabolic Risk and Frailty Through Sarcopenic Obesity.

Journal of the American College of Cardiology·2026
Same journal

Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.

Journal of the American College of Cardiology·2026
Same journal

The Measure of a Leader: Lessons in Leadership From Eugene Braunwald.

Journal of the American College of Cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Cardiorenal syndrome.

Claudio Ronco1, Mikko Haapio, Andrew A House

  • 1Department of Nephrology, St. Bortolo Hospital, Vicenza, Italy. cronco@goldnet.it

Journal of the American College of Cardiology
|November 15, 2008
PubMed
Summary
This summary is machine-generated.

A new classification for cardiorenal syndrome (CRS) defines 5 subtypes based on heart and kidney dysfunction. This framework aids in understanding the bidirectional relationship and guides diagnosis and treatment for CRS patients.

More Related Videos

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
10:25

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

Related Experiment Videos

Last Updated: Jun 28, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury
10:25

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

Area of Science:

  • Cardiology
  • Nephrology
  • Pathophysiology

Background:

  • The term cardiorenal syndrome (CRS) lacks a consistent definition, hindering understanding of heart-kidney interactions.
  • Existing knowledge does not fully capture the complex, bidirectional relationship between cardiac and renal dysfunction.

Purpose of the Study:

  • To introduce a novel 5-subtype classification for cardiorenal syndrome (CRS).
  • To provide a framework reflecting the pathophysiology, timeframe, and nature of heart and kidney dysfunction in CRS.
  • To improve the characterization, management, and clinical trial design for CRS.

Main Methods:

  • Defined CRS as a disorder where dysfunction of one organ induces dysfunction in the other.
  • Developed 5 subtypes based on the directionality and acuity of cardiac and renal involvement.
  • Highlighted the role of biomarkers in early diagnosis and intervention.

Main Results:

  • Introduced 5 subtypes of CRS: Type 1 (cardiac to kidney, acute), Type 2 (cardiac to kidney, chronic), Type 3 (kidney to cardiac, acute), Type 4 (kidney to cardiac, chronic), and Type 5 (systemic).
  • Emphasized the bidirectional nature of heart and kidney interactions in CRS pathophysiology.
  • Proposed that this classification aids in patient stratification and clinical trial design.

Conclusions:

  • The proposed 5-subtype classification offers a standardized approach to understanding cardiorenal syndrome.
  • This classification facilitates targeted management strategies and enhances the precision of clinical research in CRS.
  • Biomarkers are crucial for early CRS detection and timely therapeutic interventions.